Company overview. coretech lt, UAB is a Lithuanian private limited liability company (UAB) registered in Vilnius on 19 November 2018, code 304953472, with its registered office at Švitrigailos g. 32, LT-03230 Vilnius. It is the parent/holding entity for the group that trades publicly as Oxylabs, a web-data company founded in 2015 inside the Tesonet business ecosystem. Ownership is private; in July 2026 Warburg Pincus took a minority stake via a US$130M investment at a reported US$3.6B group valuation. Entity-level filings for coretech lt, UAB show roughly 118–127 insured employees and about €7.1M sales revenue (2024); group figures reported in press are far larger (Oxylabs claims ~$350M annual recurring revenue, 350,000+ customers, and 160+ patents). Press accounts of group headcount vary widely (roughly 500 to 2,000+), so treat that figure as unverified.
Products / services. Oxylabs operates web data collection infrastructure: data-center and residential proxy networks, web-scraping APIs and crawlers, and an AI-focused data-collection platform (Oxylabs AI Studio). Group subsidiaries named in court filings and registry data include Code200, UAB; Metacluster LT, UAB; Oxysales, UAB; and Teso LT, UAB. The group acquired Webshare (2022) and ScrapingBee (2025).
Patent-litigation posture. Operating company, not an NPE. Per the case data it has 0 plaintiff cases and 1 defendant case. That single tracked matter is the Federal Circuit appeal captioned Bright Data Ltd. v. Code200, UAB et al. (Nos. 2023-2144 et al.), in which coretech lt, UAB appears as an appellee alongside affiliated entities — consistent with a company being sued, not asserting patents. Israeli competitor Bright Data (f/k/a Luminati) originally filed infringement suits in the Eastern District of Texas (E.D. Tex. Nos. 2:19-cv-00395 and 2:19-cv-00396) against Teso/Oxysales/Metacluster/Coretech and Code200.
Notable context. Coretech was also a named petitioner in the related PTAB inter partes reviews, which found Bright Data's data-communication patents (including U.S. 11,044,342 and 10,257,319) unpatentable. On 1 August 2025 the Federal Circuit affirmed those findings, a defense-side win for the Oxylabs-affiliated defendants.